Centessa Pharmaceuticals plc (LON:0ACX)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 2.52B +43.4% |
| Revenue (ttm) | 11.16M +118.9% |
| Net Income | -180.55M |
| EPS | -1.35 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 8 |
| Average Volume | 377 |
| Open | 23.60 |
| Previous Close | 23.20 |
| Day's Range | 23.60 - 23.60 |
| 52-Week Range | 9.86 - 30.54 |
| Beta | 1.57 |
| RSI | 45.99 |
| Earnings Date | Mar 27, 2026 |
About Centessa Pharmaceuticals
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines. Its lead clinical-stage program includes ORX750, an orally administered OX2R agonist in a Phase 2a study for the treatment of idiopathic hypersomnia and narcolepsy type 1 and 2. The company also develops ORX142 for the treatment of neurological and neurodegenerative disorders, as well as other potential symptoms, including excessive daytime sleepiness, impaired attention, cognitive deficits, and fatigue; and ORX489 for the treatme... [Read more]
News
Nxera Pharma to Receive $1.8 Million Milestone Payment from Centessa Pharmaceuticals
Tokyo, Japan and Cambridge, UK, 12 February 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today notes that Centessa Pharmaceuticals has achieved an early development milestone ass...
FMR LLC's Strategic Acquisition of Centessa Pharmaceuticals Shares
FMR LLC's Strategic Acquisition of Centessa Pharmaceuticals Shares
First Week of CNTA January 2027 Options Trading
Investors in Centessa Pharmaceuticals PLC (Symbol: CNTA) saw new options become available this week, for the January 2027 expiration. One of the key data points that goes into the price an option buye...
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
BOSTON and LONDON, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines f...
This Fund Locked In Gains With a $14.5 Million Biotech Exit Amid a Staggering Stock Rally
Centessa Pharmaceuticals develops therapies for rare and serious diseases, advancing a pipeline of clinical-stage and emerging candidates.
Truist Securities Raises Price Target on CNTA to $38, Maintains Buy Rating | CNTA Stock News
Truist Securities Raises Price Target on CNTA to $38, Maintains Buy Rating | CNTA Stock News
First Week of CNTA March 20th Options Trading
Investors in Centessa Pharmaceuticals PLC (Symbol: CNTA) saw new options begin trading this week, for the March 20th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down...
Centessa Pharmaceuticals Announces Poster Presentation of New Preclinical Data Supporting Expansion of Orexin Receptor 2 (OX2R) Agonist Pipeline into Neuropsychiatric Indications at the 64th ACNP Annual Meeting
Antidepressive effects and enhanced wakefulness were observed with OX2R activation in established animal model of major depressive disorder Antidepressive effects and enhanced wakefulness were observe...
Nxera Pharma to Receive US$3.6 Million in Milestone Payment Pursuant to Research Collaboration with Centessa
Tokyo, Japan and Cambridge, UK, 13 January 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) notes that Centessa Pharmaceuticals has achieved an early development milestone associated...
Centessa Pharmaceuticals Enters Oversold Territory (CNTA)
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a tec...
Chardan Capital Maintains Buy Rating for Centessa Pharmaceuticals (CNTA) | CNTA Stock News
Chardan Capital Maintains Buy Rating for Centessa Pharmaceuticals (CNTA) | CNTA Stock News
Centessa (CNTA) Sees Significant Decline in Stock Price
Centessa (CNTA) Sees Significant Decline in Stock Price
Centessa Pharmaceuticals CEO Saurabh Saha To Step Down; Mario Accardi Named Replacement
(RTTNews) - Centessa Pharmaceuticals plc (CNTA), a clinical-stage pharmaceutical company, Thursday announced that its chief executive officer Saurabh Saha will step down from his role on January 1, 20...
Centessa Pharmaceuticals Announces CEO Transition as Company Advances Strategy to Extend Orexin Leadership into Multiple Neuroscience Indications
Mario Alberto Accardi PhD, President and founder of Centessa's Orexin Program, appointed Chief Executive Officer and member of the Board of Directors Mario Alberto Accardi PhD, President and founder o...
Oppenheimer Raises Centessa Pharmaceuticals (CNTA) Price Target to $62 | CNTA Stock News
Oppenheimer Raises Centessa Pharmaceuticals (CNTA) Price Target to $62 | CNTA Stock News
Insider Sell Alert: Mario Accardi Sells 10,000 Shares of Centessa Pharmaceuticals PLC
Insider Sell Alert: Mario Accardi Sells 10,000 Shares of Centessa Pharmaceuticals PLC
What One Fund's Sale of Centessa Stock Signals About the Fast-Rising Biotech Company
Here's why a fast-rising pharmaceutical trimmed—and not abandoned—by a specialist fund signals ongoing conviction in the stock.
Interesting CNTA Put And Call Options For July 2026
Investors in Centessa Pharmaceuticals PLC (Symbol: CNTA) saw new options become available this week, for the July 2026 expiration. One of the key data points that goes into the price an option buyer i...
Centessa Stock Has Surged 77% Over the Past Year — But a Top Biotech Fund Is Still Buying
A science-first biotech fund is leaning deeper into one company just as its lead program delivers some compelling early neuro data.
Why Centessa Pharmaceuticals Stock Crushed the Market Today
Investors were optimistic about the company potentially reaping $250 million in gross proceeds from an equity offering.
Centessa Pharmaceuticals Shares Jump 17% On $250 Mln Public Offering Announcement
(RTTNews) - Centessa Pharmaceuticals plc (CNTA) rose 17.65% to $26.52, up $3.98, after announcing it has priced an underwritten public offering of 11.63 million American Depositary Shares - ADSs at $2...
Centessa (CNTA) Sees 14% Surge in Stock Price
Centessa (CNTA) Sees 14% Surge in Stock Price
Centessa Prices Public Offering At $21.50 Per ADS
(RTTNews) - Centessa Pharmaceuticals plc (CNTA) has priced its underwritten public offering of 11.63 million American Depositary Shares ("ADSs"), each representing one ordinary share, at $21.50 per AD...
Centessa Pharmaceuticals (CNTA) Launches $250M Public Offering
Centessa Pharmaceuticals (CNTA) Launches $250M Public Offering
Centessa Pharmaceuticals prices $250M offering at $21.5 per ADS
Centessa Pharmaceuticals (CNTA) priced an underwritten public offering of ~11.63M ADSs, each representing one ordinary share, at a price to the public of $21.50 per ADS.